Introduction

Join our Sales team as a Manager of Field Account South and play a key role in driving commercial performance across the assigned territory through effective sales execution, customer engagement, and opportunity governance. In this field-based leadership role, you will guide Field Account Managers, strengthen customer relationships, and ensure disciplined account execution to accelerate growth and support better health for more people. This position is based in Hyderabad, India and requires extensive customer-facing engagement across the territory.

Grow with us – Your Responsibilities

• Drive territory sales execution by reviewing pipeline trends, monitoring opportunity progression, and initiating corrective actions across active opportunities to achieve quarterly and annual revenue objectives within the assigned territory

• Strengthen customer-centric engagement by steering multi-level relationship coverage and value positioning across assigned accounts, positioning Sartorius as a trusted partner to increase customer satisfaction, share of wallet, and long-term territory growth

• Align with Business Unit Technical Sales teams to coordinate early technical engagement and solution positioning across opportunities, helping address customer-specific needs and barriers while improving opportunity conversion

• Ensure sales process discipline through CRM (SFDC) compliance, rigorous opportunity qualification, high-quality documentation, and data-driven pipeline review practices to improve forecast accuracy, data quality, and sales cycle efficiency

• Govern execution of account plans across the territory by tracking progress, resolving escalations, and addressing execution gaps to maintain customer satisfaction and accelerate opportunity advancement

• Drive adoption of the commercial operating model by monitoring process adherence, collaboration between Account Management and Technical Sales teams, and completion of required enablement activities to ensure consistent execution and scalable commercial performance

What will convince us

• Bachelor’s degree in Life Sciences, Engineering, Business, or a related field

• 10+ years of commercial experience within the life sciences industry, including first-line field sales management experience

• Proven hunter mindset with a successful track record of identifying, developing, and winning new business opportunities

• Strong data-driven sales leadership capabilities with expertise in CRM discipline, forecasting accuracy, pipeline analytics, and KPI-based sales management

• Demonstrated expertise in solution-based and value-based selling within complex customer environments

• Strong collaboration skills with the ability to work effectively across a matrix organization

• Excellent communication and influencing skills with the ability to drive commercial outcomes across a distributed field organization

• Willingness to travel more than 50% as this role is heavily focused on external customer engagement

About Sartorius

Sartorius is part of the solution in the fight against cancer, dementia, and many other diseases. Our technologies help translate scientific discoveries into real-world medicine faster, so that new therapeutics can reach patients worldwide.

We look for ambitious team players and creative minds, who want to contribute to this goal and advance their careers in a dynamic global environment.

Join our global team and become part of the solution. We are looking forward to receiving your application.
www.sartorius.com/careers

About the company

Sartorius provides laboratory and bioprocessing equipment and services for the biopharmaceutical industry. Its two divisions, Bioprocess Solutions and Lab Products & Services, supply systems, consumables, and analytics used in biotech drug and vaccine development and production. It differentiates itself with a long history, an integrated portfolio, global support, and acquisitions like BioOutsource to offer end-to-end solutions. Its goal is to help biopharmaceutical companies develop and manufacture biotech products more reliably and at scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Get referred to Sartorius

See people who can refer or advise you

Simplify's Take

What believers are saying

H1 2026 operational sales rose 7.7%, and management reaffirmed full-year guidance.
May 2026 bond refinancing lowered funding pressure before the €650 million maturity.
ElevateBio pilot validation and September 2026 ordering support Eveo sales conversion in 2027.

What critics are saying

Tariff refunds and customer compensation cut 2026 revenue by up to €35 million.
Lab Products grew only 5.3% operationally in H1 2026, lagging Bioprocess Solutions.
Delayed advanced-therapy orders from two customers shift revenue into 2027, hurting execution confidence.

What makes Sartorius unique

Eveo launches March 16, 2026, integrating cell therapy manufacturing and QC in one system.
Bioprocess Solutions dominates with high-recurring consumables and switching costs across biologics manufacturing.
Stedim Biotech integration gives Sartorius tighter control over single-use bioprocessing and global customer relationships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Flexible Work Hours
Wellness Program
Professional Development Budget

Company News

Yahoo Finance

Oct 23rd, 2026

Sartorius Stedim Biotech nine-month sales up 7.8% to $2.5B, full-year guidance confirmed

Sartorius Stedim Biotech reported nine-month sales growth of 7.8% in constant currencies, or 6.5% after tariff-related customer compensation. Sales reached €2.29 billion, driven by strong consumables and a recovering equipment business. Underlying EBITDA rose 4.8% to €716 million, with a margin of 31.3%. Underlying net profit climbed 9.4% to €350 million, and free cash flow jumped 58.5% to €264 million. Net debt stood at €2.14 billion, or 2.26 times underlying EBITDA. Americas growth lagged at 3.9% including tariff compensation, hurt by project delays in Advanced Therapies. The company confirmed full-year guidance: operational sales growth near the midpoint of 6% to 10% and an underlying EBITDA margin slightly above 31%.

Yahoo Finance

Jul 23rd, 2026

Sartorius reports 7.7% sales growth as bioprocess equipment stabilises

Sartorius reported solid first-half results, with constant-currency sales up 7.7% and underlying EBITDA rising 3.9% as margins improved to 30.3%. Management confirmed full-year guidance. Bioprocess Solutions led performance, growing 8.3% in constant currencies. Consumables drove growth, whilst equipment stabilised slightly. Chief executive Michael Grosse said demand for biologics remains robust, particularly in monoclonal antibody manufacturing. However, advanced-therapy orders from two customers were delayed and could shift revenue into 2027. Tariff refunds and accounting effects distorted reported results but did not change underlying business trends. The company booked €26 million in customer compensation related to tariffs. Operating cash flow and free cash flow both improved sharply in the first half.

AD HOC NEWS

May 15th, 2026

Sartorius completes full takeover of Stedim Biotech, delisting bioprocessing unit from Euronext Paris

Sartorius Stedim Biotech is set to be delisted from Euronext Paris following a squeeze-out by majority shareholder Sartorius Group. The voluntary tender offer and subsequent acquisition process, which began in early 2024, will transition the company from a separately traded stock into a fully integrated part of Sartorius Group. Headquartered in Aubagne, France, Sartorius Stedim Biotech develops bioprocessing equipment and single-use technologies for biopharmaceutical manufacturing. Its products include bioreactors, filtration systems and process automation tools used by pharmaceutical and biotech companies globally. North America represents a key market, with many US-based biopharma firms using its technologies. The company experienced normalised growth following pandemic-era demand surges, with customers working through elevated inventories accumulated during vaccine production. Despite short-term headwinds, long-term demand drivers remain supported by expanding biologics and advanced therapy pipelines.

wallstreet:online AG

May 6th, 2026

Sartorius completes $560M bond placement with 3.75% coupon to refinance existing debt

Sartorius has completed a €500 million bond placement via its Dutch subsidiary Sartorius Finance B.V. The five-year bond, targeted at institutional investors, was more than four times oversubscribed and carries a 3.75% annual coupon. The life science group will use the proceeds for general corporate purposes, including refinancing existing debt. This includes the redemption of a €650 million bond with a 4.25% interest rate due in autumn 2026. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange. Chief financial officer Florian Funck said the successful issuance strengthens the company's balanced debt maturity profile and long-term financing position, whilst demonstrating investor confidence in Sartorius' strategic direction.

Sartorius